Janssen secures FDA approval for Tecvayli to treat multiple myeloma
Tecvayli is an off-the-shelf, subcutaneous therapy, indicated for subcutaneous administration for the treatment of relapsed or refractory multiple…
We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More X
26 Oct 22
Tecvayli is an off-the-shelf, subcutaneous therapy, indicated for subcutaneous administration for the treatment of relapsed or refractory multiple…
26 Oct 22
Taysha Gene Therapies is engaged in developing gene therapies for the treatment of Rett syndrome and giant axonal…
25 Oct 22
The transaction is anticipated to close in the first quarter of 2023, subject to certain customary closing conditions,…
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates
25 Oct 22
Not only sports celebrities have announced their attendance at MEDICA 2022, the programme of the forums integrated into…
25 Oct 22
The approval by the US regulator was based on the findings of the HIMALAYA phase 3 trial which…
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates
21 Oct 22
DJS Antibodies is engaged in the development and commercialisation of antibody medicines that target difficult-to-drug disease-causing proteins, and…
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates
21 Oct 22
Roche will pay an upfront amount of $25m to HOOKIPA Pharma and potential payments of up to $930m…
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates
20 Oct 22
Under the terms of the deal, Jazz will obtain exclusive rights to develop and commercialise zanidatamab worldwide, excluding…
20 Oct 22
The FDA Emergency Use Authorisation decision was based on the findings of the phase 3 Prevent-19 clinical trial…
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates
19 Oct 22
"We're excited to launch these limited-edition wafers and cookies that were inspired by classic holiday flavors like gingerbread,…